Who are the key players in North America DNA Diagnostics Market industry?

Key players include Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, Illumina Inc., and Bio-Rad Laboratories. These companies dominate the market through continuous product innovation, robust distribution networks, and extensive research and development in molecular diagnostics, enhancing their service portfolios and increasing their regional market share.

What is the North America DNA Diagnostics Market growth?

The North America DNA Diagnostics Market is experiencing robust growth, driven by increasing adoption of precision medicine and technological advancements. For instance, Illumina Inc. has reported double-digit sales growth in its sequencing solutions, fueled by rising demand for genetic testing across healthcare facilities in the region.

Which segment accounted for the largest North America DNA Diagnostics Market share?

In 2023, the oncology segment accounted for the largest share of the North America DNA Diagnostics Market. The increasing prevalence of cancer and the use of DNA-based tests for early cancer detection have significantly accelerated segment growth, with companies like Roche Diagnostics leading in the development of high-sensitivity oncology diagnostics.

What are the factors driving the North America DNA Diagnostics Market?

The primary market drivers include rising cases of genetic disorders, increased awareness of personalized medicine, and technological progression in diagnostic platforms. For example, Thermo Fisher Scientific’s recent investments in next-generation sequencing platforms have accelerated adoption and expanded clinical applications throughout North America.

Which type accounted for the largest North America DNA Diagnostics Market share?

Polymerase Chain Reaction (PCR) technology accounted for the largest share of the North America DNA Diagnostics Market. PCR remains a preferred method for various genetic tests due to its high accuracy, sensitivity, and widespread application in infectious disease testing, oncology, and hereditary disorder screening.

Home Healthcare

North America DNA Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: North America DNA Diagnostics Market
Brand: Bussiness Insights

North America DNA Diagnostics Market: by Type (PCR-Based Diagnostics, Microarray-Based Diagnostics, Sequencing Technology, In Situ Hybridization, Mass Spectrometry, Others), Application (Infectious Diseases, Oncology, Genetic Testing, Pharmacogenomics, Forensic Testing, Others), Distribution Channels (Hospitals, Diagnostic Laboratories, Point of Care, Research Institutes, Direct to Consumer, Others), Technology (PCR, NGS, Microarrays, In Situ Hybridization, Mass Spectrometry, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20233 | Author: Ankit

RD TOC Segmentation Research Methodology Request For Free Sample

North America DNA Diagnostics Market – Comprehensive Growth Analysis and Forecast (2020-2035)

North America's DNA diagnostics market is experiencing significant transformation due to advancements in genomics and increased focus on personalized medicine. The adoption of innovative technologies like next-generation sequencing (NGS), PCR-based diagnostics, and improvements in bioinformatics has accelerated the efficiency and accessibility of DNA diagnostics across various healthcare segments. Growing investments in research, increasing prevalence of genetic disorders, expanding use in oncology and infectious diseases, and strategic partnerships among key players are shaping the industry’s trajectory. The region’s regulatory landscape is fostering innovation, while the rising demand for direct-to-consumer genetic testing and pharmacogenomics presents robust growth opportunities for market players.

Latest Market Dynamics

Key Drivers

Rising prevalence of chronic and genetic diseases: The increased incidence of cancer, rare genetic disorders, and infectious diseases in North America is driving demand for advanced DNA-based diagnostic solutions. Recent product launches by

in early cancer detection exemplify this trend.

Rapid advancements in diagnostic technology: The integration of next-generation sequencing and digital PCR is enhancing the speed and accuracy of DNA diagnostics. For example, Illumina's recent updates to its NGS platforms in 2024 have significantly improved throughput and data quality.

Growth in direct-to-consumer genetic testing: Consumer demand for DNA testing kits from companies like 23andMe and Myriad Genetics is surging, driven by increased awareness and interest in ancestry and health risk profiling.
Expansion of pharmacogenomics: The rise in personalized medicine is leading to greater adoption of pharmacogenomic DNA tests, with Thermo Fisher Scientific expanding its pharmacogenomics portfolio in 2024.

Key Opportunities

Adoption of AI and bioinformatics in diagnostics: Companies like Qiagen are leveraging AI-driven analytics to interpret complex genomic data, improving clinical decision-making and opening new market segments.
Increased integration with electronic health records (EHRs): Recent collaborations between Epic Systems and Abbott Laboratories are enabling seamless integration of DNA diagnostic data into EHRs, enhancing patient care coordination.

Data privacy and security concerns: The explosion of sensitive genetic data collection has heightened the risk of breaches, with recent incidents highlighting the need for more robust security frameworks across diagnostic platforms.
High cost of advanced diagnostics: Despite technological progress, the high cost of NGS and other sophisticated DNA diagnostics platforms from players like Illumina can limit access for smaller labs and institutions.

Regulatory uncertainties: Shifting regulatory policies, especially concerning direct-to-consumer genetic testing, challenge market expansion. Recent FDA updates have led to delays in test approvals for companies like 23andMe.
Limited reimbursement coverage: Insurance coverage for advanced DNA diagnostics remains inconsistent, particularly impacting smaller diagnostics labs and limiting the wider adoption of new technologies.

Market Share by Type (2025)

To learn more about this report,Download Free Sample Report

In 2025, the DNA diagnostics market in North America is led by PCR-Based Diagnostics, accounting for almost half of the total market. Sequencing Technology follows, reflecting its growing use in high-throughput applications and oncology. Microarray-Based Diagnostics also hold a notable share, particularly in research and pharmacogenomics. The diverse range of diagnostic solutions is catering to varied clinical, research, and consumer demands.

Market Share by Application (2025)

To learn more about this report,Download Free Sample Report

The top application area for DNA diagnostics in North America remains oncology, reflecting the growing emphasis on precision medicine in cancer care. Infectious diseases testing is also prominent, driven by persistent threats like COVID-19 and antimicrobial resistance. Genetic testing is expanding rapidly, driven by greater consumer access and the need for early, non-invasive diagnostics in a range of diseases.

North America DNA Diagnostics Market Revenue (2020-2035)

To learn more about this report,Download Free Sample Report

The revenue for the North America DNA diagnostics market has shown steady growth, supported by technological innovation and extended applications across healthcare. Moving from $7,950 Million in 2020 to a projected $23,400 Million by 2035, the sector highlights strong investment flows and increasing adoption of advanced diagnostics in medical settings.

Year-Over-Year Growth Rate (2020-2035)

To learn more about this report,Download Free Sample Report

Year-over-year (YoY) growth for the North America DNA diagnostics market averages between 7% and 11% throughout the forecast period. The period between 2024 and 2028 sees the fastest acceleration, attributed to expanding clinical applications of NGS and the post-pandemic surge in diagnostic awareness. The rate stabilizes as market maturity approaches toward 2035.

Market Share by Region (2025)

To learn more about this report,Download Free Sample Report

The US dominates the North American DNA diagnostics market with approximately 75% of total revenue, reflecting its advanced healthcare infrastructure and R&D leadership. Canada and Mexico contribute 15% and 10%, respectively, driven by increased healthcare investments, but remain smaller due to market scale and regulatory variations.

Market Players Share (2025)

To learn more about this report,Download Free Sample Report

Top players such as Roche Diagnostics and Thermo Fisher Scientific collectively command 34% of the North American DNA diagnostics market in 2025. The remaining share is distributed among key innovators like Abbott Laboratories, Illumina, Qiagen, and a number of emerging companies, highlighting a competitive and dynamic landscape.

Market Buyers Share (2025)

To learn more about this report,Download Free Sample Report

Hospitals retain the largest share of DNA diagnostics product purchases at 40%, given their role in acute and chronic patient management. Diagnostic laboratories follow due to centralized testing, while research institutes and direct-to-consumer channels contribute modest but rising shares.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	11500
Regions	US, Canada, Mexico
Segments	By Type, By Application, By Technology, By Distribution Channels, By Organization Size
Players	Roche Diagnostics, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories, Hologic Inc., Illumina Inc., Qiagen, Agilent Technologies, Danaher Corporation, Becton Dickinson & Company, Cepheid, Genomic Health, Myriad Genetics, Luminex Corporation, Siemens Healthineers

Key Recent Developments

June 2024: Thermo Fisher Scientific launches a new high-throughput NGS system tailored for oncology diagnostics.
July 2024: Roche Diagnostics receives FDA Emergency Use Authorization for a rapid PCR-based COVID-19 test expansion.
August 2024: Qiagen partners with Microsoft to integrate AI-powered bioinformatics analysis into its DNA diagnostics platform.
September 2024: Illumina announces cloud-based software solutions to enhance data sharing for clinical diagnostics labs.
October 2024: Abbott Laboratories and Epic Systems announce full-scale interoperability for genetic diagnostic results in EHRs.

Frequently Asked Questions

About the Author

Ankit

Senior Research Consultant

Ankit is a Senior Research Consultant specializing in market research, industry analysis, and business consulting across Healthcare. Ankit brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Ankit has helped organizations translate data into actionable growth strategies.

HealthcareMarket ResearchIndustry AnalysisStrategic Consulting

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Download Sample

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

Speak to Analyst

North America DNA Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America DNA Diagnostics Market – Comprehensive Growth Analysis and Forecast (2020-2035)

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

Market Share by Type (2025)

Market Share by Application (2025)

North America DNA Diagnostics Market Revenue (2020-2035)

Year-Over-Year Growth Rate (2020-2035)

Market Share by Region (2025)

Market Players Share (2025)

Market Buyers Share (2025)

Study Coverage

Key Recent Developments

Frequently Asked Questions

About the Author

Related Reports